Pursuant to Reg 34 of SEBI Listing Regulations, please find enclosed the Annual Report of the Company for the FY 2025-26.

SUDARSHAN PHARMA INDUSTRIES LTD Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092. E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997 SPIL/CS/SE/2026-2027/55 Date: 29th August, 2026 The Listing Department BSE Scrip Code: 543828 BSE Limited BSE Trading Symbol: SUDARSHAN Phiroze Jeejeebhoy Towers, ISIN: INE00TV01023 Dalal Street, Mumbai – 400 001 Dear Sir / Madam, Sub: Annual Report of the Company for the Financial Year 2025-26 ----------------------------------------------------------------------------------------------------------------- Dear Sir / Madam, Pursuant to Regula(cid:415)on 34 of the SEBI (Lis(cid:415)ng Obliga(cid:415)ons And Disclosure Requirements) Regula(cid:415)ons, 2015, please find enclosed the Annual Report of the Company for the Financial Year 2025-26. Pursuant to circulars issued by the Ministry of Corporate Affairs and Securi(cid:415)es and Exchange Board of India, the Annual Report for Financial Year 2025-26 is being sent electronically to all the members of the Company whose email addresses are registered with the Company / Depository Par(cid:415)cipants. Request you to take the same on record. Yours truly, For, Sudarshan Pharma Industries Limited Nirav Shah Company Secretary & Compliance Officer Encl: As above Regd. Off.: 301, Aura Biplex, Above Kalyan Jewellers, S.V. Road, Borivali (West), Mumbai - 400092. SSUUDDAARRSSHHAANN Sudarshan Pharma Industries Limited 2026 18TH ANNUAL REPORT 2025-26 Annual Report 2025-26 1 SSUUDDAARRSSHHAANN Sudarshan Pharma Industries Limited TABLE OF FINANCIAL STATEMENTS CONTENTS 90 Standalone Financial Statements 171 Consolidated Financial Statements CORPORATE OVERVIEW Forward-looking Statements 04 Corporate Information In this Annual Report, we have disclosed forwardlooking information to enable investors to comprehend 05 Chairman’s Message our prospects and take investment decisions. This Report and other statements – written and oral – that we periodically make contain forward-looking 07 Joint Managing Director’s Message statements that set out anticipated results based on the management’s plans and assumptions. We have 10 Brief Profile of the Directors tried, wherever possible, to identify such statements by using words such as ‘anticipate’, ‘estimate’, ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’ and words of 19 Management Discussion & Analysis similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realised, although we believe we have been prudent in our assumptions. The achievements of results are subject to risks, uncertainties and even inaccurate assumptions. STATUTORY Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove REPORTS inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should keep this in mind. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events 43 Notice or otherwise. 52 Board’s Report To get this report online and for any other information log on to: 69 Report on Corporate Governance www.sudarshanpharma.com Annual Report 2025-26 3 SSUUDDAARRSSHHAANN Sudarshan Pharma Industries Limited Annual Report 2025-26 Corporate Information Board of Directors Internal Auditor Mr. Hemal Vasantrai Mehta M/s. Uttam Nahar & Co. Founder, Chairman & Managing Director Mr. Sachin Vasantrai Mehta Secretarial Auditor Founder & Joint Managing Director (CFO upto 01-May-2025) Dr. Umesh Luthra Mr. Vishal Manseta Independent Director Mrs. Jaya Ankur Singhania Independent Director Bankers Mr. Rushabh Patil Independent Director Union Bank of India Mr. Sanat Bhat Axis Bank Limited Independent Director (w.e.f. 1st May 2026) ICICI Bank Limited Kotak Mahindra Bank Limited Dr. Anil Ghogare Non-Executive Director Dr. Vinay Pandey Non-Executive Director Registered Office (w.e.f. 1st May 2026) Chief Financial Officer 301,3rd Floor, Aura Biplex, Above Kalyan Jewellers, S. V. Road, Borivali (West), Mr. Manoj Lodha Mumbai-400092 (w.e.f. 1st May 2025 and resigned on 5th August 2025) Email ID: compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Mr. Sharad Kathawate (w.e.f. 1st May 2026) Registrar and Share Company Secretary & Transfer Agent Compliance Officer KFin Technologies Limited Mr. Nirav Kishor Shah Selenium Tower B, Plot No. 31 & 32, Statutory Auditors Financial District, Serilingampally Mandal, Hyderabad- 500 032 Email ID: compliance.corp@kfintech.com M/s. NGST & Associates Phone: +91-40-67162222/7961 1000 CORPORATE OVERVIEW STATUTORY REPORTS | FINANCIAL STATEMENTS Chairman’s Message Dear Shareholders, I am honoured to communicate with you through the Annual Report. Our journey over the decades has been characterised by resilience, innovation, and an unwavering commitment to delivering healthcare solutions for millions of individuals worldwide. As we navigate the DOMESTIC complexities of our global landscape, increasingly affected by the challenges of progressive climate change, heightened human conflict, DEMAND and protectionist policies, our dedication to these principles remains resolute. $1,000 billion Fiscal 2026 represented a period of recalibration and thoughtful innovation. Our commercial strategy, together with an integrated operating model, enabled us to navigate effectively through an environment characterised by geo-political uncertainties while by year 2040 maintaining stable performance. India is expected to account for more than 20% of incremental global consumption of chemicals over the next two decades. Domestic demand is expected to rise from $170 billion to $180 billion in 2021 to $850 billion to $1,000 billion by 2040. billi SSUUDDAARRSSHHAANN Sudarshan Pharma Industries Limited Annual Report 2025-26 We stimulated our manufacturing capabilities, ventured into new opportunities and established ambitious goals for long-term sustainable growth. As we progress, we will maintain a rigorous focus on disciplined execution and operational efficiency in light of ongoing global uncertainties. We acquired the capital assets — comprising land, building, and plant & machinery at a fully operational manufacturing facility located in Telangana which will result into massive growth in the Company’s manufacturing capacity and substantially accelerate its trajectory in the high-growth Active Pharmaceutical Ingredients (API) and specialty chemicals sectors, resulting into incremental footprint in the domestic and global market. The facility will be utilized for the production of high-value, technically complex pharmaceutical ingredients including Ropivacaine, Bupivacaine, Probenecid (Probalan), Sitagliptin, Apixaban, and Rivaroxaban—critical APIs and intermediates with strong demand across regulated and semi- regulated markets. We have always believed that our purpose is way beyond just making profits; it is to create exceptional experiences as we continue our relentless journey towards excellence. It isn’t just about achieving specific goals; it’s about the transformation that is, and will continue to happen in the process. A transformation that will firmly position the Company on the road to greater heights. We continue to strive in its efforts to develop new line of products based on its capabilities and also through new business associations. We continue to prioritize sustainable compliance across all our manufacturing units, further reinforcing our position as a trusted partner. As we move forward, we are committed to creating a sustainable and prosperous future for all our stakeholders. Your continued support and trust are invaluable to us, and we look forward to achieving many more milestones together. We look forward to connecting with you again. Reg [Showing first 8,000 characters — download PDF for full document]